Calmune, Crucell enter research, development deal

Calmune Corp. announced Nov. 3 that it has entered an agreement with Crucell N.V. that will focus on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Financial details of the deal were not disclosed.


Under this collaboration, Calmune will use a proprietary technology to prepare a panel of potent, high-affinity human monoclonal antibodies (hMabs) against a pre-defined, undisclosed infectious disease target. Crucell will have the option to exclusively license these hMabs for further evaluation as development candidates, and to develop any that meet its requirements.


Calmune will receive payments from Crucell at different stages of the discovery and development process, as well as a royalty on sales of products that incorporate antibodies generated by Calmune.


“Calmune’s demonstrated technological expertise in the generation of potent human monoclonal antibodies is a valuable complement to Crucell’s existing research programs and opens the door to the development of new therapeutics for infectious diseases,” said Dr. Jaap Goudsmit, chief scientific officer of Crucell.


Calmune is a privately held biotechnology company in San Diego that develops antibody therapeutics designed to address unmet clinical needs.


Crucell is a global biopharmaceutical company based in Leiden, the Netherlands, that is focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its existing vaccines protect against influenza, hepatitis A, hepatitis B and typhoid fever. It has vaccines in development against yellow fever, Marburg and Ebola, among other biological agents.